Erudio Bio, Inc.

posted: 26-Mar-2026 & updated: 27-Mar-2026

Date: March 26, 2026
To: Kim Yujin, Manager, BSR Korea
From: Sunghee Yun, Ph.D., Co-Founder & CTO @ Erudio Bio / Co-Founder & CEO @ Erudio Bio Korea
Re: Singapore/ASEAN Market Entry - Strategic Questions

Question 1 - Strategic Goals for Singapore/ASEAN Market

Question

Learn more about each company’s strategic goals: Are they primarily seeking market validation, regulatory guidance, investment, strategic partnerships, or a combination? What are their target timelines and success metrics for the Singapore/ASEAN market?

Answer

Erudio Bio is seeking a combination of all the elements mentioned.

Market Validation

  • Clinical validation of VSA platform in Singapore/ASEAN hospital settings
  • Demonstration of cost-effectiveness compared to existing multiplex assay solutions
  • Real-world performance data in diverse patient populations

Regulatory Guidance

  • Navigation of HSA (Health Sciences Authority, Singapore) regulatory pathways
  • Understanding of ASEAN medical device harmonization requirements
  • Support for clinical trial design and approval processes

Investment

  • Strategic investors with ASEAN market expertise and network
  • Co-investment opportunities aligned with Gates Foundation follow-on funding (~$5M indicated)
  • Partners who understand biotech infrastructure business models

Strategic Partnerships

  • Hospital networks for clinical validation and commercial deployment
  • Distribution partners for equipment and consumables
  • Research collaborations with Singapore’s biomedical research institutions (A*STAR, etc.)

Target Timeline

Year Milestone
2026 Initial partnership discussions, regulatory pathway assessment
2027 Clinical validation studies, regulatory submissions
2028-2029 Commercial launch in Singapore, expansion to ASEAN markets

Success Metrics

  • 3-5 hospital partnerships in Singapore/ASEAN by end of 2027
  • Regulatory approval (Singapore HSA) by 2028
  • 50,000+ patient samples analyzed by 2029
  • Market presence in at least 3 ASEAN countries by 2029

Question 2 - Current Stage of Development - PoC Readiness

Question

Understand their current stage of development: Are they ready for a PoC now, or do they require earlier-stage support? What are their key technical or commercial milestones?

Answer

Yes, Erudio Bio is ready for PoC (Proof of Concept) deployment now.

Current Development Stage:

Technology Maturity:

  • VSA platform: Fully functional benchtop system with validated performance
  • Demonstrated capability: 50-100 molecular interactions per 10µL sample
  • bioTCAD AI platform: Operational with Gates Foundation validation

Clinical Validation Status:

Korea:

  • IRB-approved studies in progress at Seoul National University Bundang Hospital (SNUBH) and Keimyung University Dongsan Hospital

China:

  • Joint Development Agreement (JDA) executed with Shanghai General Hospital (National Clinical Research Center for Eye Diseases)
  • ~$1M equivalent in-kind contribution

Biomarkers validated:

  • 6-marker cancer panel (AFP, CA19-9, CA125, CEA, FT4, TSH)

Technical/Commercial Milestones Already Achieved:

✅ 21 patents filed/granted (dynamic force spectroscopy core technology)
✅ $1M Gates Foundation competitive grant (August 2025) - validates both technology and team
✅ Three signed hospital partnerships with major institutions
✅ Manufacturing partnership with Analog Devices (ADI) for chip production scalability
✅ Advisory board including Stanford and Harvard faculty

Key Technical Milestones for Singapore PoC:

  • Adapt biomarker panels to regional disease prevalence (e.g., hepatitis B-related cancers, nasopharyngeal carcinoma)
  • Validate platform performance with Singaporean/ASEAN patient samples
  • Demonstrate integration with local hospital laboratory workflows

Key Commercial Milestones:

  • Establish cost-effectiveness vs existing solutions (target: 1/3 price of current 6 separate tests)
  • Generate Singapore-specific clinical evidence for reimbursement pathways
  • Build local service and support infrastructure

Erudio Bio can initiate Singapore PoC immediately upon partnership establishment.

Question 3 - Anticipated Pain Points and Barriers for Singapore/ASEAN Entry

Question

Identify any specific pain points or barriers they anticipate in entering the region, so we can align our resources accordingly.

Answer

Regulatory & Compliance

  • HSA regulatory pathway navigation Understanding classification (IVD vs. medical device) and required clinical evidence
  • ASEAN harmonization Adapting to different regulatory requirements across ASEAN markets (Malaysia, Thailand, Indonesia, etc.)
  • Data privacy compliance Meeting Singapore’s PDPA (Personal Data Protection Act) and healthcare data security requirements
  • Quality management Establishing ISO 13485 compliance documentation for the region

Clinical & Scientific

  • Disease prevalence differences ASEAN has different cancer epidemiology (higher hepatocellular carcinoma, nasopharyngeal carcinoma) requiring panel adaptation
  • Biomarker validation Need to validate existing markers and potentially add region-specific markers
  • Clinical evidence generation Establishing clinical utility in local patient populations
  • Hospital workflow integration Adapting to different laboratory information systems (LIS) and hospital IT infrastructure

Commercial & Market Access

  • Hospital partnership establishment Building relationships with Singapore’s public healthcare clusters (SingHealth, NHG, NUHS) and private hospitals
  • Reimbursement pathways Understanding Singapore’s healthcare financing (MediShield, integrated shield plans, corporate insurance)
  • Pricing strategy Balancing affordability with sustainability given Singapore’s cost-conscious healthcare system
  • Distribution & logistics Establishing local supply chain for consumables, reagents, and equipment maintenance

Operational

  • Local presence requirement Establishing Singapore entity vs. operating through distributors
  • Technical support infrastructure Providing timely maintenance and troubleshooting for hospital-based equipment
  • Training programs Developing training materials and certification for local laboratory technicians
  • Cultural adaptation Understanding local healthcare decision-making processes and relationship-building protocols

Competitive Landscape

  • Incumbent relationships Existing multiplex assay providers (Luminex, Olink, etc.) have established hospital relationships
  • Market education Educating clinicians on advantages of force spectroscopy vs. traditional binding assays
  • Demonstration of value Proving cost-effectiveness and clinical utility in Singapore’s evidence-based healthcare system

Financial

  • Currency and payment terms Managing multi-currency operations and understanding local payment cycles
  • Import duties and taxes Understanding cost structure including GST and import regulations
  • Funding clinical studies Securing resources for Singapore-specific validation studies

Strategic Support Needed from Partners

  • Regulatory consulting and submission support
  • Introductions to hospital decision-makers (lab directors, procurement)
  • Clinical validation study design and CRO connections
  • Reimbursement strategy consulting
  • Distribution and service network establishment

Question 4 - Regulatory Status in Asia & Commercial Model Fit

Questions

First, understand Erudio’s readiness: What is its regulatory status in Asia? Do they have a commercial model that fits the regional healthcare ecosystem? What specific support do they need from a partner like Tamarind?

Answer

A. Current Regulatory Status in Asia

Korea (Most Advanced)

  • Status Clinical validation in progress, targeting MFDS (Ministry of Food and Drug Safety) approval in 2027
  • Entity Erudio Bio Korea, Inc. (established July 2025)
  • Clinical Studies IRB-approved studies at SNUBH and Keimyung University Dongsan Hospital
  • Classification In vitro diagnostic (IVD) device for cancer biomarker detection
  • Strategy Leveraging multi-site validation (Seoul + regional) to strengthen MFDS submission

China

  • Status Early-stage clinical collaboration
  • Partnership Joint Development Agreement (JDA) executed with Shanghai General Hospital
  • Focus National Clinical Research Center for Eye Diseases (uveitis and related conditions)
  • Contribution ~$1M equivalent in-kind contribution from hospital
  • Regulatory Path NMPA (National Medical Products Administration) pathway to be determined based on Shanghai validation results
  • Strategy Hospital partnership provides clinical data and pathway to Chinese market; US Entity retains China market rights per US-Korea term sheet

Singapore/ASEAN

  • Status Not yet initiated; seeking initial partnerships
  • Readiness Technology platform is validated; requires region-specific clinical data
  • Approach Partner-led regulatory strategy depending on initial collaboration structure

United States

  • Status Research Use Only (RUO) phase for diagnostic applications; preclinical for drug discovery platform
  • Gates Foundation Project bioTCAD drug discovery AI platform ($1M grant, non-diagnostic application)
  • Future Path FDA 510(k) or PMA pathway to be determined post-Korea approval

B. Commercial Model Fit for Regional Healthcare Ecosystem

Our Multi-Revenue Stream Model

1. Equipment Sales (Hardware)

  • VSA benchtop reader system
  • High-margin model (70%+ gross margin)
  • One-time capital equipment purchase by hospitals
  • Regional Fit Singapore hospitals have capital budgets for advanced diagnostic equipment; this model works well in high-resource settings

2. Consumables (Recurring Revenue)

  • Microfluidic chips (proprietary sensor arrays)
  • Reagent kits for specific biomarker panels
  • Repeat purchase model creates recurring revenue
  • Regional Fit Aligns with Singapore’s pay-per-test healthcare economics; hospitals prefer operational expense vs. large capital outlays for some applications

3. Service Fees (Per-Sample Analysis)

  • Analysis service fee per patient sample (~$150-300 USD equivalent)
  • Includes data analysis, QC, and clinical report generation
  • Regional Fit Compatible with Singapore’s healthcare pricing structure; cost-competitive vs. sending 6 separate tests (current standard)

4. SaaS Platform (Subscription)

  • bioTCAD AI platform for drug discovery applications (separate revenue stream)
  • Cloud-based molecular interaction analysis
  • Subscription or per-project licensing
  • Regional Fit Singapore is regional biotech/pharma hub; strong market for drug discovery tools

Alignment with ASEAN Healthcare Ecosystem

Singapore Specifically

  • Public Healthcare (70% of population) MediShield coverage + government subsidies; our cost-effectiveness (1/3 price vs. current) fits subsidy optimization
  • Private Healthcare (30%) International patients and corporate insurance; willing to pay for premium diagnostics
  • Research Institutions A*STAR, medical schools; strong demand for advanced research tools (RUO sales)

Broader ASEAN

  • Tiered Approach Singapore as anchor market → expand to Malaysia, Thailand (strong healthcare systems) → eventually Vietnam, Indonesia
  • Flexibility Can adapt model (equipment sales vs. service model) based on local hospital infrastructure and payment systems
  • Regional Hub Strategy Singapore as distribution and technical support center for ASEAN

C. Specific Support Needed from Partner Like Tamarind Health

Clinical Validation Partnership

  • Access to patient samples for biomarker validation studies
  • Clinical data generation for regulatory submissions
  • Real-world evidence collection for health economics studies
  • Physician champion identification and engagement

Regulatory Navigation

  • HSA submission strategy and documentation support
  • Clinical trial design aligned with regulatory requirements
  • Quality management system (QMS) establishment in Singapore
  • Post-market surveillance setup

Commercial Pathway

  • Introductions to hospital procurement decision-makers across Tamarind network
  • Understanding of hospital budgeting cycles and purchasing processes
  • Reimbursement strategy consulting and payer engagement
  • Pricing strategy aligned with regional healthcare economics

Strategic Relationship Type - Our Perspective

We view Tamarind Health as potentially

  1. Clinical Validation Partner (primary, near-term): Provide patient access and clinical data
  2. Strategic Distribution Partner (medium-term): Distribute across their hospital network
  3. Co-Development Partner (if interested): Jointly develop Singapore/ASEAN-specific diagnostic panels
  4. Investment Opportunity (if aligned): Strategic investment with commercial partnership

Our Ideal Partnership Structure

  • Phase 1 (2026-2027) Clinical validation collaboration at 1-2 Tamarind-affiliated hospitals
  • Phase 2 (2027-2028) Pilot commercial deployment across Tamarind network
  • Phase 3 (2028+) Full commercial partnership with revenue-sharing or distribution agreement

What We Bring to Partnership

  • Proven technology with hospital validation (Korea, China)
  • $1M Gates Foundation grant validation (technical and team credibility)
  • 21 patents protecting core technology
  • Stanford/Harvard scientific advisory board
  • US-Korea dual entity structure enabling flexible partnership models
  • Manufacturing partnership with Analog Devices for scale

D. Summary - Readiness Assessment

Area Status
Technology ✅ Fully ready for Singapore deployment
Clinical Evidence ⚠️ Partial (Korea/China in progress); needs Singapore-specific data
Regulatory ⚠️ Not yet filed; require 12-18 months for HSA pathway
Commercial Model ✅ Proven in Korea; highly adaptable to Singapore ecosystem
Team ✅ Experienced (Stanford/Samsung/Amazon backgrounds); capable of regional expansion
Funding ✅ Current + Gates follow-on (~$5M) provides runway; open to strategic regional investors

Optimal Partnership Timing Initiate discussions NOW for 2026 clinical validation launch.

Conclusion

Please let us know if Templewater/Tamarind Health would like a detailed presentation or preliminary discussion call. We are very interested in Singapore/ASEAN market entry and view this as a strategic priority for 2026-2027.

Best regards,

Sunghee Yun, Ph.D.
Co-Founder & CEO, Erudio Bio Korea, Inc.
Co-Founder & CTO, Erudio Bio, Inc.

Contact

  • Email: sunghee.yun@gmail.com
  • Mobile (US): +1-408-549-4077
  • Mobile (Korea): +82-10-6500-7045

This document provides strategic responses to BSR Korea’s questions regarding Erudio Bio’s Singapore/ASEAN market entry strategy, prepared for discussions with Templewater and Tamarind Health networks.